373. An open-label 24-week randomised multicentered clinical trial of Bictegravir/Emtricitabine/Tenofovir Alafenamide compared to Tenofivir/Lamifuvine/Efavirenz as an initial regimen in Chinese late presenters with HIV-1 infection

BACKGROUND: Despite tremendous efforts, late presenters (CD4 ≤ 350 cells/μl) still account for a staggering proportion of HIV patients at the time of diagnosis. The main objective of this study was to evaluate the viral-immunological efficacy of bictegravir/emtricitabine/ tenofovir alafenamide (BIC/...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Ling, Lu, Ruichao, Wang, Rugang, Zhou, Yingquan, Wei, Hongxia, Ma, Ping, Zhang, Junyan, Lyu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677676/
http://dx.doi.org/10.1093/ofid/ofad500.443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677676/
http://dx.doi.org/10.1093/ofid/ofad500.443

Ejemplares similares